Immunovant

IMVTPhase 3

New York, United StatesFounded 2018immunovant.com

Immunovant is dedicated to enabling normal lives for people with autoimmune diseases by developing targeted anti-FcRn therapies. The company's lead assets, batoclimab and IMVT-1402, are in clinical development for a range of IgG-mediated conditions, with positive Phase 2b results recently announced for batoclimab. As a subsidiary of Roivant Sciences, Immunovant leverages a patient-focused, innovative approach to address complex autoimmune disease needs.

Market Cap

$4.7B

Founded

2018

Focus

AntibodiesBiologics

IMVT · Stock Price

USD 22.98+17.41 (+312.57%)

Historical price data

AI Company Overview

Technology Platform

Platform of anti-neonatal Fc receptor (anti-FcRn) monoclonal antibodies designed to inhibit IgG recycling, promoting the degradation of pathogenic immunoglobulin G (IgG) autoantibodies that drive autoimmune diseases.

Pipeline Snapshot

19 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
Batoclimab + Placebo	Thyroid Eye Disease	Phase 3
Batoclimab	Thyroid Eye Disease	Phase 3
Batoclimab 680 mg SC weekly + Batoclimab 340 mg SC weekly + Matching Placebo SC ...	Generalized Myasthenia Gravis	Phase 3
IMVT-1402 + IMVT-1402 + Placebo + IMVT-1402	Generalized Myasthenia Gravis	Phase 3
Batoclimab + Placebo	Thyroid Eye Disease	Phase 3

Funding History

Total raised: $625M

PIPE$350MRA Capital ManagementFeb 15, 2021

IPO$200MUndisclosedOct 25, 2019

Series A$75MRA Capital ManagementOct 15, 2018

Opportunities

The large and growing market for IgG-mediated autoimmune diseases, estimated at over 2 million patients, presents a significant opportunity.

Success with its next-generation candidate, IMVT-1402, could position Immunovant with a potential best-in-class therapy with an improved tolerability profile.

The subcutaneous administration route offers a competitive advantage in patient convenience over intravenous alternatives.

Risk Factors

Key risks include clinical trial failures, regulatory setbacks, and intense competition from established players with approved FcRn inhibitors.

As a pre-revenue company, Immunovant is also dependent on capital markets for funding its expensive late-stage clinical programs.

Competitive Landscape

Immunovant competes in the anti-FcRn space against approved therapies like Argenx's Vyvgart and UCB's rozanolixizumab, as well as late-stage candidates from large pharma like Johnson & Johnson's nipocalimab. Its differentiation strategy focuses on tailored dosing and developing next-generation candidates with potentially improved tolerability profiles.

Publications

Patents

Pipeline